TherapeuticsMD Inc (NASDAQ:TXMD) – Analysts at Jefferies Financial Group issued their FY2023 EPS estimates for shares of TherapeuticsMD in a research report issued on Wednesday, February 6th. Jefferies Financial Group analyst C. Howerton forecasts that the company will post earnings per share of $0.87 for the year.
TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Wednesday, November 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. TherapeuticsMD had a negative return on equity of 102.15% and a negative net margin of 757.59%. The company had revenue of $3.47 million during the quarter, compared to analysts’ expectations of $4.43 million. During the same quarter in the previous year, the company posted ($0.07) earnings per share. The business’s revenue was down 21.5% on a year-over-year basis.
Shares of NASDAQ:TXMD opened at $5.23 on Thursday. TherapeuticsMD has a 12-month low of $3.51 and a 12-month high of $7.66. The company has a market cap of $1.28 billion, a PE ratio of -14.14 and a beta of 2.06. The company has a debt-to-equity ratio of 0.55, a current ratio of 7.23 and a quick ratio of 7.15.
Several hedge funds have recently modified their holdings of the stock. We Are One Seven LLC acquired a new position in TherapeuticsMD during the fourth quarter valued at approximately $26,000. Dfpg Investments Inc. acquired a new position in TherapeuticsMD during the fourth quarter valued at approximately $38,000. Stevens Capital Management LP acquired a new position in TherapeuticsMD during the third quarter valued at approximately $101,000. B. Riley Wealth Management Inc. acquired a new position in TherapeuticsMD during the third quarter valued at approximately $102,000. Finally, Creative Planning acquired a new position in TherapeuticsMD during the fourth quarter valued at approximately $63,000. Institutional investors and hedge funds own 73.20% of the company’s stock.
In related news, CFO Daniel A. Cartwright sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, December 6th. The stock was sold at an average price of $4.57, for a total value of $182,800.00. Following the completion of the sale, the chief financial officer now directly owns 40,000 shares in the company, valued at $182,800. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Brian Bernick sold 182,800 shares of the business’s stock in a transaction that occurred on Tuesday, November 20th. The shares were sold at an average price of $4.74, for a total value of $866,472.00. Following the completion of the sale, the director now owns 242,000 shares of the company’s stock, valued at $1,147,080. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,578,475 shares of company stock valued at $11,847,963. 22.85% of the stock is currently owned by corporate insiders.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
See Also: Short Selling
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.